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Abstract
Background: Expression of periostin is an indicator of epithelial-mesenchymal transition in cancer but a detailed 
analysis of periostin expression in prostate cancer has not been conducted so far.
Methods: Here, we evaluated periostin expression in prostate cancer cells and peritumoural stroma 
immunohistochemically in two independent prostate cancer cohorts, including a training cohort (n = 93) and a test 
cohort (n = 325). Metastatic prostate cancers (n = 20), hormone refractory prostate cancers (n = 19) and benign 
prostatic tissues (n = 38) were also analyzed.
Results: In total, strong epithelial periostin expression was detectable in 142 of 418 (34.0%) of prostate carcinomas and 
in 11 of 38 benign prostate glands (28.9%). Increased periostin expression in carcinoma cells was significantly 
associated with high Gleason score (p < 0.01) and advanced tumour stage (p < 0.05) in the test cohort. Whereas 
periostin expression was weak or absent in the stroma around normal prostate glands, strong periostin expression in 
tumour stroma was found in most primary and metastatic prostate cancers. High stromal periostin expression was 
associated with higher Gleason scores (p < 0.001). There was a relationship between stromal periostin expression and 
shortened PSA relapse free survival times in the training cohort (p < 0.05).
Conclusions: Our data indicate that periostin up-regulation is related to increased tumour aggressiveness in prostate 
cancer and might be a promising target for therapeutical interventions in primary and metastatic prostate cancer.
Background
Periostin (POSTN) is a 93 kDa N-glycoprotein, first
described in 1993 in mouse osteoblasts as osteoblast-spe-
cific factor 2 (OSF-2). It shows homology with the cell
adhesion molecules fasciclin 1 (drosophila) and beta-
IgH3 (human), sharing features that are thought to
explain some of its functional characteristics [1,2] like
involvement in cell adhesion and osteoblast recruitment
[3].
Periostin has been found in several, mainly collagen-
rich and fetal tissues as an extracellular matrix protein
and is up-regulated by mechanical stress during tissue
repair and (re)generation [4-8]. Periostin expression can
be induced by vascular injury which in turn induces vas-
cular endothelial growth factor receptor 2 with conse-
quent promotion of angiogenesis [9,10]. After myocardial
infarction, periostin up-regulation seems to be important
for the healing process [11,12].
As a ligand to alpha(V)beta(3) and alpha(V)beta(5)
integrin periostin appears to activate the Akt/PKB (pro-
tein kinase B) pathway, known to facilitate cell survival
and tumourigenesis [13-15].
High expression of periostin protein or mRNA was
detected in most solid tumours including breast, colon,
head and neck, pancreatic, papillary thyroid, ovarian,
lung, gastric and liver carcinoma, as well as neuroblas-
toma [9,13,16-33]. As periostin is a secreted protein, it is
not surprising that elevated periostin levels in serum and
pleural effusion have recently been detected in lung can-
cer patients [28,34]. Suggested effects of periostin on
tumour cells include increased growth and resistance
against hypoxia and chemotherapeutics [16,17].
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Page 2 of 9So far there is only a single report on periostin expres-
sion in prostate cancer [35]. Increased cancer cell expres-
sion of periostin compared to normal glands was found
during early stages of prostate cancer whereas in
advanced stages stromal periostin expression prevailed
[35]. The aim of our study was to determine the periostin
expression in the stromal and epithelial compartment of
the tumour, as well as the correlation with clinical data
including patient follow up data in a larger cohort.
Methods
Patients
A training cohort was used for the establishment of a
periostin evaluation algorithm. The training cohort con-
sisted of tissue of 93 prostate cancer patients diagnosed
between 1990 and 2001 at the Institute of Pathology,
Charité - Universitätsmedizin Berlin. In this cohort cases
with and without PSA relapse were selectively chosen to
study the relevance of biomarkers for prediction of PSA
relapse. The median age was 61 years (range 47-73 years).
The pT-status was pT2 in 42 (45.2%) and pT3/4 in 51
(54.8%) cases. The Gleason score was < 7 in 23 (24.7%), 7
in 39 (41.9%) and >7 in 31 (33.3%) cases. Forty-one
(44.1%) tumours were judged R1, 50 (53.8%) R0 and 2
(2.1%) Rx. Forty-three (46.2%) patients had a PSA relapse.
The median follow-up time was 45 months (range 3-180
months).
In a second step, periostin expression was analyzed in a
larger test cohort with 325 primary prostate cancers. The
test cohort consisted of 325 consecutive patients treated
with prostatectomy for prostate cancer between 1993 and
2006 at the Department of Urology, University Hospital
Zurich. The median age was 64 years (range 46-79 years).
The pT-status was pT2 in 205 (63.1%) and pT3/4 in 120
(36.9%) cases. The Gleason score was < 7 in 50 (15.4%), 7
in 194 (59.7%) and >7 in 81 (24.9%) tumours. Concerning
surgical margins, 112 (34.5%) tumours were R1, 207
(63.7%) R0 and 6 (1.8%) Rx. Sixty-eight (20.9%) patients
had a PSA relapse. The median follow-up time was 72
months (range 0-163 months). Data on relapse free sur-
vival times was available for 211 of the patients. In addi-
tion 20 metastatic prostate cancers (organ metastasis; 19
bone metastasis and 1 bladder metastasis), 19 hormone
resistant prostate cancers and 38 cases of benign pros-
tatic tissue were evaluated. The 19 hormone resistant
prostate cancer specimens were from patients undergo-
ing palliative transurethral prostate resection in advanced
disease.
The study was approved by the the Charité University
Ethics Committee (EA1/06/2004) and by the Cantonal
Ethics Committee of Zurich (StV 25-2007 neu). In the lat-
ter, necessity of patients' informed consent was explicitely
ruled out, since this is a retrospective study.
Tissue microarray construction
The tissue microarrays (TMA) were constructed as previ-
ously described [36]. We used commercially available tis-
sue arrayers (Beecher Instruments, Woodland, CA, USA)
and applied a core diameter of 0.6 mm for the tissue sam-
ples of Zurich and 1.0 mm for the tissue samples of Ber-
lin. Each tumour was represented by one tissue core.
Immunohistochemistry (IHC)
The TMA blocks were freshly cut (3 μm) and mounted on
superfrost slides (Menzel Gläser, Braunschweig, Ger-
many). IHC was conducted with the Ventana Benchmark
automated staining system (Ventana Medical Systems,
Tucson, AZ, USA) using Ventana reagents and a poly-
clonal antibody against human periostin (OSF-2/perios-
tin, BioVendor Laboratory Medicine, Modrice, Czech
Republic; RD181045050 RD-932, 1:500) after standard
(CC1 m) heat induced antigen retrieval as described
before [32]. The antibody dilution was titrated using
small test arrays as described elsewhere [32]. Detection
was performed using the UltraVIEW™ DAB detection kit.
Evaluation of stainings
The periostin protein expression was evaluated by two
clinical pathologists (FRF, GK) on a multi-headed micro-
scope. The test cohort was subsequently re-evaluated by
another pathologist (AS).
For evaluation of epithelial and stromal periostin
expression, we implemented an immuno-reactive score
including intensity and quantity of cells stained. The
staining intensity was scored negative (0), weak (1+),
moderate (2+) or strong (3+). The quantity of stained
cells was scored zero (0), < 10% (1+), 10-50% (2+), 51-80%
(3+) or >80% (4+). Intensity and quantity were multiplied
(immunoreactive score (IRS), range 0-12).
Statistical analysis
Statistical analyses were performed with SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). The median value of the IRS was
used as cut-off point to dichotomize the tumours into a
"periostin low" and "periostin high" group. Fisher's exact
and chi-squared tests were applied to assess associations
between categorized periostin expression and clinico-
pathological parameters. Correlations were computed
using Spearman's bivariate rank order correlation. Uni-
variate survival analysis was carried out according to
Kaplan-Meier, differences in survival curves were
assessed with the Log rank test. P-values < 0.05 were con-
sidered significant.
Results
Periostin expression in epithelia and stroma of prostate 
tissues
Distinct stromal and epithelial staining characteristics
allowed an absolutely certain evaluation of the periostin
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Page 3 of 9staining (Figure 1a and 1b). Benign prostate glands
expressed high stromal periostin in only 2/38 cases and
high epithelial periostin in 11/38 cases. From the 38
benign prostate samples, 24 displayed no periglandular
stromal and 14 no epithelial periostin expression. Of the
24 benign cases without stromal periostin expression, 19
showed epithelial periostin expression and vice versa of
the 14 benign cases without periostin expression, 9
revealed stromal periostin expression. Both periostin epi-
thelial and stromal negativity occurred in 5 of the benign
cases. Five cases were positive for periostin in both epi-
thelia and stroma. Basal cells showed in some cases a
slightly stronger staining than the inner secretory cell
layer. In the remaining tumour epithelia, periostin was
detected in the cytoplasm without luminal or membra-
nous accentuation. Nuclear staining was not observed.
The stroma displayed a fibrillary pattern with consider-
able variation of intensity. Staining intensity differed fre-
quently within a respective case between the stroma and
epithelium.
Tumour stroma was positive in all cases of the training
cohort and most cases of the test cohort. Only 11 (3.4%)
cases of the test cohort were negative. An IRS above 2
was found in the vast majority of primary (82.8%), hor-
mone resistant (78.9%) and metastatic (85%) tumours.
Using our periostin score, it was possible to differentiate
between low and high periostin expression levels using
the median. The median stromal IRS for both primary
prostate cancer cohorts was 6 with a mean value of about
5.5.
Sixty (18.5%) primary prostate cancer cases showed no
epithelial periostin expression and 189 (58.2%) cases had
an IRS equal to or below 3 (median 3). In total, 142/418
prostate cancer cases expressed high levels of epithelial
periostin. Only 7.4% of cases exhibited an IRS for epithe-
lial periostin expression above 6. Revalidation of the
stainings resulted in the same median IRS values.
For the 19 hormone resistant prostate cancers the
median IRS was 8 for the stromal and 4 for the epithelial
periostin expression (means: 6.8 and 5.1). In the 20 sam-
ples from prostate cancer metastases the mean and
median IRS of epithelial and stromal periostin expression
did not differ from that in the primary prostate cancers.
Correlations and associations with clinico-pathological 
parameters
In the training cohort, stromal periostin expression
showed no correlation (Spearman rank order) with any of
the clinico-pathological parameters (age, pT-status, Glea-
son score, residual status). A higher pT stage was signifi-
cantly associated with high epithelial periostin expression
(p = 0.026, Table 1). However, Fisher's exact test revealed
a significant association of higher periostin stromal
expression with positive resection margins (R1) (high
periostin expression in R0 versus R1: 14% (n = 7) versus
39% (n = 16); p = 0.008). No other associations were
detected (Table 1). In the test cohort, high stromal and
epithelial periostin expression were both associated with
high Gleason scores (p = 0.011 and 0.007, Table 2). For
epithelial expression an additional significant association
with advanced pT-status was demonstrated (p = 0.048,
Table 2). In the Spearman rank order correlation for the
test cohort, the significant associations from above could
be confirmed for epithelial expression (p-values: 0.001
and 0.047, Table 3). For stromal expression, the correla-
tion with Gleason score was also significant (p = 0.003,
Table 3). Stromal periostin expression was significantly
correlated with epithelial periostin expression (p = 0.003,
Table 3).
Periostin and PSA relapse free survival
The standard prognosticators (pT-status, Gleason score
and residual tumour) correlated significantly with short-
ened PSA relapse free survival in both cohorts (Table 4,
training cohort not shown). In the training cohort, high
Figure 1 Periostin protein expression in malignant and benign 
prostate tissue. Weak (a) to moderate (b) epithelial and negative (a) 
to weak (b) stromal periostin expression in benign prostate glands. In 
contrast to most cancer cases, in benign tissue with stromal periostin 
expression the direct periglandular area is rather negative. Some cases 
showed a weak periostin positivity of basal cells. Prostate cancers with 
negative (c), weak (d), moderate (e/f2) and strong (e inset) epithelial 
periostin expression. The peritumoural stroma was weakly (c), moder-
ately (d) or strongly (f1/f2) positive.
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Page 4 of 9stromal periostin was significantly associated with short-
ened PSA relapse free survival times (p < 0.05; Figure 2a).
In the test cohort, neither stromal nor epithelial perios-
tin expression reached prognostic significance (relapse
free survival, p = 0.373 respectively p = 0.722) (Figure 2b).
Discussion
In this study, we provide evidence for periostin up-regu-
lation during prostate cancer progression. Periostin
expression was found in both epithelial cancer cells and
in peritumoural stroma. Recently, our group has demon-
strated that periostin as a marker for the epithelial-mes-
enchymal-transition (EMT) programme in lung cancer is
prognostically relevant [32]. EMT is correlated with
tumour progression and represents an important form of
tumour-stroma interaction facilitating the stromal inva-
sion of the cancer cells. Periostin seems to play an impor-
tant part in this prognostically adverse
transdifferentiation process. However, the regulation
mechanisms of periostin in tumour progression have not
been elucidated so far. Our data demonstrate a significant
association between periostin and pT-stage, Gleason
grade and involvement of prognosis in two different pros-
tate cancer cohorts, suggesting that EMT is of utmost
importance for prostate cancer progression. There is only
one study by Tsunoda et al. observing a prostate cancer
patient cohort of 77 prostate cancers showing increased
periostin expression in early prostate cancer stages as
well as in the stroma of advanced prostate cancer cases
[35]. This is in contrast to our study of 418 prostate carci-
nomas where we find increased epithelial periostin
expression positively correlated to grade and stage and
increased stromal periostin positively correlated to grade.
Augmentation of both epithelial and stromal periostin in
our cohort is a characteristic of the advanced and more
aggressive prostate cancer cases. This observation is fur-
ther supported by the finding that only 2/38 benign pros-
tate tissues expressed stromal periostin. The differences
of Tsunoda et al. and our results may be explained by the
sample number (77 versus 418) and differences in grade
and stage. Our test cohort was represented by 63.1% pT2
and 36.9% pT3/4 tumours whereas Tsunoda's cohort
comprised of 18.2% pT2 and 74.0% pT3/4 tumours. Grade
in our test cohort was < 7 in 15.4%, 7 in 59.7% and >7 in














All cases 93(100) 45 (48.4) 48 (51.6) 87 (93.5) 6 (6.5)
Age 0.905/
0.484
≤ 64 49 (52.7) 24 (49.0) 25 (51.0) 45 (91.8) 4 (8.2)
>64 44 (47.3) 21 (47.7) 23 (52.3) 42 (95.5) 2 (4.5)
pT-status 0.573/0.026
pT2 42 (45.2) 22 (52.4) 20 (47.6) 42 (100) 0 (0)
pT3/4 51 (54.8) 23 (45.1) 28 (54.9) 43 (84.3) 6 (11.7)
Gleason score 0.523/
0.404
3-6 23 (24.8) 13 (56.5) 10 (43.5) 22 (95.7) 1 (4.3)
7 39 (41.9) 19 (48.7) 20 (51.3) 38 (97.4) 1 (2.6)
8-10 31 (33.3) 13 (41.9) 18 (58.1) 27 (87.1) 4 (12.9)
Residual tumoura 0.322/
0.052
R0 50 (54.9) 26 (52.0) 24 (48.0) 49 (98.0) 1 (0.02)
R1 41 (45.1) 17(41.5) 24 (58.5) 36 (87.8) 5 (12.2)
aTwo cases were Rx
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Page 5 of 924.9%. Tsunoda's cohort had a much higher percentage of
Gleason 8-10 of 55.8%. Altogether, our test cohort might
be more representative for early stages of prostate cancer
than Tsunoda's which could well explain the observed dif-
ference.
We do acknowledge that a core diameter of 0.6 mm per
prostate cancer case might not be fully representative for
a given case. This is especially of importance in small
cohorts. However, during the preparation of our tissue
microarray, we reviewed each case very carefully to
choose a representative area of tumour tissue.













All cases 325 (100) 224 (68.9) 101 (31.1) 189 (58.2) 136 (41.8)
Age 0.120/
1.000
≤ 64 165 (50.8) 107 (64.8) 58 (35.2) 96 (58.2) 69 (41.8)
>64 160 (49.2) 117 (73.1) 43 (26.9) 93 (58.1) 67 (41.9)
pT-status 0.710/0.048
pT2 205 (63.1) 143 (69.8) 62 (30.2) 128 (62.4) 77 (37.6)
pT3/4 120 (36.9) 81 (67.5) 39 (32.5) 61 (50.8) 59 (49.2)
Gleason score 0.011/
0.007
3-6 50 (15.4) 40 (80.0) 10 (20.0) 35 (70.0) 15 (30.0)
7 194 (59.7) 136 (70.1) 58 (29.9) 116 (59.8) 78 (40.2)
8-10 81 (24.9) 48 (59.3) 33 (40.7) 38 (46.9) 43 (53.1)
Residual tumoura 0.451/
0.634
R0 207 (63.7) 139 (67.1) 68 (32.9) 119 (57.5) 88 (42.5)
R1 112 (34.5) 80 (71.4) 32 (28.6) 68 (60.7) 44 (39.3)
aSix cases were Rx
Table 3: Periostin protein expression (stromal and epithelial) with clinico-pathological parameters in the test cohort
Periostin Periostin stromal Periostin epithelial pT-status Gleason sum Age Residual tumour
Periostin epithelial
CC 0.162 0.057 0.162 -0.108 -0.020
p-value 0.003 0.307 0.003 0.053 0.720
Number of cases 325 325 325 325 319
Periostin epithelial
CC 0.162 0.110 0.191 -0.056 -0.027
p-value 0.003 0.047 0.001 0.313 0.626
Number of cases 325 325 325 325 319
CC = Correlation coefficient
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Page 6 of 9There are several reports on involvement of other EMT
markers eg. platelet-derived growth factor-D, hypoxia-
inducible factor-1α and zinc finger enhancer binding pro-
tein 1 in prostate cancer [37-40]. Meanwhile, periostin
has been found up-regulated in several tumour entities,
either in the stroma, the epithelial cells or in the serum
[17,26,27,30,41,42]. In most of these tumour entities,
periostin has been associated with more aggressive
tumour characteristics, which is perfectly in line with our
findings in prostate cancer. Apart from EMT, periostin is
related to other stromal re-modeling and repair processes
such as wound healing or formation of heart valves in
embryogenesis. It is not clear yet whether periostin
upregulation reflects only the stroma re-modeling pro-
cess per se or whether it is actively induced by the
tumour cells themselves. The presence of both mRNA
and protein in the cytoplasm of tumour cells favours
an active or signal transducting role of periostin,
respectively. Further functional studies are needed to
shed light on the mechanism of periostin up-regulation
in prostate cancer.
In our test cohort we could not reproduce the promis-
ing results concerning the prognostic value of periostin
deduced from the training cohort. A possible explanation
is most likely the selection of the training cohort with a
very high number of cases with PSA relapse (46%)
whereas the consecutive cases of the test cohort show
usual relapse rates (21%). The selection of the training
cohort was done to identify biomarker for PSA relapse. It
is not uncommon to see that prognostic significances are
better in trainings cohorts than in tests cohorts. The dif-
fering results for relapse free survival of both cohorts are
therefore not too surprising for us, also taking into
account that the composition of the cohorts is so differ-
ent. However, this also demonstrates that the prognostic
value of periostin is limited in comparison to well estab-
lished conventional prognosticators of prostate cancer
and other potentially prognostic molecular markers
[36,43]. More important than a prognostic value of
periostin might be its use as a therapeutic target. Kudo et
al. and Castranovo et al. have recently evaluated its thera-
peutic potential [41,44]. In a chemical proteomics
approach, periostin was found accessible by the blood
stream, which is an important factor for effective druga-
bility [41,44]. It has been concluded that its expression
characteristics and cancer specific up-regulation make
periostin a promising target for ligand-based tumour tar-
geting strategies. Considering its high expression in both
stroma and tumour cells, this might be an auspicious
option for advanced prostate cancer. Also, the diagnostic
serological value of periostin might be worth looking at.
Conclusions
This immunohistochemical study describes the periostin
protein expression pattern in prostate cancer and benign
prostate tissue in a large patient cohort. Its upregulation
in primary, metastatic and hormone resistant prostate
cancers was related to a more aggressive and advanced
tumour biology. These expression characteristics and its
proposed drugability make periostin a promising target
for an individualized prostate cancer therapy.
Figure 2 PSA relapse free survival for periostin in training and 
test cohort. a) In the training cohort higher stromal periostin expres-
sion was a significant prognosticator for shortened PSA relapse free 
survival (p = 0.045). The periostin low group consisted of 70 patients of 
which 29 had a PSA relapse. In the periostin high group 14 of the 23 pa-
tients had a PSA relapse. b) In the test cohort the curve of those pa-
tients with higher stromal periostin expression remained slightly 
below that of the patients with lower stromal periostin expression (p = 
0.373). In the test cohort the periostin low group consisted of 152 pa-
tients. Forty-six patients had a PSA relapse (periostin high group: 22 of 
the 59 patients with PSA relapse).
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